| 10/09/2026 4:00 PM | Fairmount Funds Management LLC (1802528) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13D/A | |
| 10/07/2026 7:00 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 10/06/2026 3:41 PM | Spyre Therapeutics (1636282) Filer | Form 424B5 | |
| 10/02/2026 8:29 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/02/2026 8:29 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/02/2026 8:30 PM | King-Jones Heidy (1794898) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/01/2026 3:30 PM | King-Jones Heidy (1794898) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/01/2026 3:36 PM | Spyre Therapeutics (1636282) Subject Turtle Cameron (1758363) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 10/01/2026 3:05 PM | Paradigm Biocapital Advisors LP (1855655) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13G | |
| 09/30/2026 3:03 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 09/08/2026 7:01 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for SYRE and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 09/03/2026 8:33 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/03/2026 8:33 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/03/2026 8:34 PM | King-Jones Heidy (1794898) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 09/01/2026 3:57 PM | King-Jones Heidy (1794898) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/25/2026 3:04 PM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/14/2026 4:22 PM | PERCEPTIVE ADVISORS LLC (1224962) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13G/A | |
| 08/14/2026 7:10 AM | RTW INVESTMENTS, LP (1493215) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13G/A | |
| 08/10/2026 8:31 PM | Albers Jeffrey W. (1638474) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/07/2026 3:39 PM | Albers Jeffrey W. (1638474) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/07/2026 3:39 PM | Albers Jeffrey W. (1638474) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 08/05/2026 8:31 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/05/2026 8:32 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 08/04/2026 3:02 PM | Spyre Therapeutics (1636282) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/04/2026 3:05 PM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/03/2026 3:51 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 07/02/2026 8:32 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 8:33 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/02/2026 8:33 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/01/2026 4:02 PM | Spyre Therapeutics (1636282) Subject Turtle Cameron (1758363) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/26/2026 8:31 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 3:05 PM | Spyre Therapeutics (1636282) Filer | Form S-3ASR | |
| 06/25/2026 3:03 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 8:56 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Kiselak Tomas (1830177) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/23/2026 8:57 PM | Fairmount Funds Management LLC (1802528) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 8:45 PM | Fairmount Funds Management LLC (1802528) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13D/A | |
| 06/23/2026 8:32 PM | HENDERSON MICHAEL THOMAS (1779990) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:44 PM | HENDERSON MICHAEL THOMAS (1779990) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/15/2026 7:01 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 8:30 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/03/2026 8:31 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Beyond NVDA: The World’s Next #1 Company? (Ad) This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvidia's.
A NASA scientist says the technology behind it is bigger than AI. Musk calls it "Amazing," and a Nobel Prize winner describes its power as "unprecedented in the history of life on Earth."
Adam O'Dell, Chief Investment Strategist at Money and Markets, names the company at the center of it all. Discover the small-cap company at the center of this tech revolution. |
| 06/03/2026 8:32 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:54 PM | Milligan Sandra (1859810) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:55 PM | McKenna Mark C. (1749623) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:55 PM | Spyre Therapeutics (1636282) Issuer Stelzer Laurie (1644348) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:55 PM | HENDERSON MICHAEL THOMAS (1779990) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:56 PM | Albers Jeffrey W. (1638474) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 4:58 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Kiselak Tomas (1830177) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/29/2026 3:45 PM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/08/2026 8:31 PM | HENDERSON MICHAEL THOMAS (1779990) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/05/2026 7:00 AM | Spyre Therapeutics (1636282) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/05/2026 7:05 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/01/2026 8:34 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 8:34 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 8:35 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/01/2026 3:44 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/01/2026 3:44 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:00 PM | PERCEPTIVE ADVISORS LLC (1224962) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13G | |
| 04/20/2026 5:00 PM | Fairmount Funds Management LLC (1802528) Filed by Spyre Therapeutics (1636282) Subject | Form SCHEDULE 13D/A | |
| 04/16/2026 3:15 PM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/13/2026 4:26 PM | Spyre Therapeutics (1636282) Filer | Form 424B5 | |
| 04/13/2026 3:29 PM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/13/2026 6:46 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/10/2026 3:12 PM | Spyre Therapeutics (1636282) Filer | Form ARS | |
| 04/03/2026 8:29 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/03/2026 8:30 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/03/2026 8:30 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 3:38 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 12:17 PM | Spyre Therapeutics (1636282) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/04/2026 11:15 PM | Spyre Therapeutics (1636282) Filer | Form EFFECT | |
| 03/03/2026 8:32 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/03/2026 8:31 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/02/2026 3:31 PM | Spyre Therapeutics (1636282) Subject Turtle Cameron (1758363) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/01/2026 11:15 PM | Spyre Therapeutics (1636282) Filer | Form EFFECT | |
| 02/19/2026 3:33 PM | Spyre Therapeutics (1636282) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 02/19/2026 3:11 PM | Spyre Therapeutics (1636282) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 02/17/2026 3:15 PM | Spyre Therapeutics (1636282) Subject TANG CAPITAL MANAGEMENT LLC (1232621) Filed by | Form SCHEDULE 13G/A | |
| 02/04/2026 8:33 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/23/2026 8:31 PM | HENDERSON MICHAEL THOMAS (1779990) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/13/2026 8:25 PM | King-Jones Heidy (1794898) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/13/2026 8:26 PM | Sloan Sheldon (2038798) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/13/2026 8:27 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/13/2026 8:27 PM | Burrows Scott L (1853327) Reporting Spyre Therapeutics (1636282) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 01/12/2026 8:00 AM | Spyre Therapeutics (1636282) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/06/2026 8:36 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 12/03/2025 8:52 PM | Spyre Therapeutics (1636282) Issuer Turtle Cameron (1758363) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |